Triglyceride Lowering Study

Hypertriglyceridemia Clinical Trial

— TGLL  

Official title:

Dose Related Decrease in Triglycerides in Patients With Hypertriglyceridemia and Treated With Lovaza.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00934219
• Other study ID #: TgLL8506
• Status: Recruiting
• Phase: Phase 4
• First received: July 7, 2009
• Last updated: July 7, 2009
• Start date: July 2009
• Est. completion date: December 2012

Study information

• Verified date: June 2009
• Source: Jewish Hospital, Cincinnati, Ohio
• Contact: LUANN SIEVE
• Phone: (513)585-7951
• Email: luann.sieve[@]healthall.com
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Lovaza is a special fish oil concentrate, that prescribed at 4 g a day to reduce certain fat (triglycerides) levels in blood.Our goal is to study how Lovaza at doses of 4, 8, and 12 grams per day will reduce fats in the blood of the patients with very high level of triglycerides. Our hypothesis is that patients with very high triglycerides will respond more with higher doses of Lovaza (8 g per day and then 12 g per day).

Description:

Lovaza contains Omega-3 fatty acids, the family of poly- unsaturated fatty acids. Omega-3 fatty acids stimulate blood circulation, increases the breakdown of fibrin, and additionally has been shown to reduce blood pressure, cardiac events and mortality from congestive heart failure. There is strong scientific evidence that omega 3 fatty acids significantly reduce blood triglyceride levels while elevating high density lipoprotein cholesterol (HDL) levels. Fasting and non fasting hypertriglyceridemia have been associated with atherosclerosis, and coronary heart disease events, even in the absence of hypercholesterolemia. Severe hypertriglyceridemia (>2000 mg/dl) can also lead to acute hemorrhagic pancreatitis.

Currently, patients having very High TG are treated with Fibric acids (gemfibrozil, Tricor, Antara), and if hyperinsulinemic, with Glucophage. Lovaza (4g/day) has been shown to be effective and safe in lowering TG levels. There is no published data which indicates that Lovaza 8 or 12 g per day would have therapeutic effectiveness in further normalizing triglycerides in subjects on maximized triglyceride lowering and Lovaza 4 g per day. We hypothesize, based on our clinical experience that increasing Lovaza to 8 and then (if necessary) to 12 g/day would safely optimize triglycerides in subjects with primary hypertriglyceridemia who failed to normalize their triglycerides on optimal therapy including Lovaza 4 g/day.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 25
• Est. completion date: December 2012
• Est. primary completion date: July 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Primary hypertriglyceridemia with fasting TG levels >1000 mg/dl, and persistence of TG levels > 500 mg/dl despite maximal TG lowering therapy for 1 month, including Lovaza 4 g/day, fibric acids, and, where indicated, Glucophage for treatment of hyperinsulinemia.

2. Patients with mild to moderately impaired renal function should be initiated on TRICOR 48 mg and patients with severe renal impairment should not be given TRICOR.

3. Absence of exclusionary criteria (see below).

Exclusion Criteria:

1. Patients with known allergy to fish

2. Hypertriglyceridemia secondary to alcoholism, exogenous estrogens, nephrotic syndrome, hemochromatosis, glycogen storage disease, uncontrolled diabetes, exogenous corticosteroids, Cushing's syndrome, uremia).

3. Bleeding gastric or duodenal ulcers, active inflammatory bowel disease.

4. Pregnancy

5. Dementia

6. Patients with bleeding diatheses

7. Patients who are taking concomitant anticoagulants and other medications that affect bleeding time (e.g., warfarin, aspirin)

8. Patients with significantly abnormal transaminases (above 3x of upper normal limit)or any history of liver disease

9. Patients with conditions affecting the skin (e.g. malignancy, vasculitides) that may confound the skin exam.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hypertriglyceridemia

Intervention

Drug:
• Omega-3-Acid Ethyl Esters
LOVAZA, 1 g caps; High Dose Arm for 4 months, while on a standard therapy for hypertriglyceridemia (fibrates, +/-metformin). Standard Dose Arm for 3 months, while on a standard, unchanged therapy for hypertriglyceridemia (fibrates +/- metformin).

Locations

Country	Name	City	State
United States	Jewish Hospital Cholesterol Center	Cincinnati	Ohio

Sponsors (2)

Lead Sponsor	Collaborator
Jewish Hospital, Cincinnati, Ohio	GlaxoSmithKline

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	triglycerides level		7 months	Yes

External Links

•   Free Triglycerides lowering study